Anixa Biosciences (NASDAQ:ANIX) Stock: Insider Amit Kumar Purchases 7,000 Shares

Anixa Biosciences Inc (NASDAQ:ANIX) CEO Amit Kumar bought 7,000 shares of the company’s stock in a transaction on Thursday, September 24th. The stock was bought at an average price of $2.78 per share, for a total transaction of $19,460.00. Following the completion of the purchase, the chief executive officer owned 672,000 shares of the company’s stock, valued at approximately $1,868,160. The trade was a 1.05% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Amit Kumar also recently made the following trade(s):

• On Thursday, September 10th, Amit Kumar purchased 3,000 shares of Anixa Biosciences stock. The shares were bought at an average price of $2.75 per share, with a total value of $8,250.00.
• On Thursday, September 10th, Amit Kumar purchased 5,000 shares of Anixa Biosciences stock. The stock was bought at an average cost of $2.76 per share, for a total transaction of $13,800.00.
• On Friday, July 31st, Amit Kumar purchased 5,000 shares of Anixa Biosciences stock. The stock was bought at an average cost of $3.47 per share, for a total transaction of $17,350.00.
• On Friday, July 24th, Amit Kumar acquired 3,000 shares of Anixa Biosciences stock. The stock was purchased at an average price of $3.73 per share, for a total transaction of $11,190.00.
• On Monday, July 20th, Amit Kumar acquired 5,000 shares of Anixa Biosciences stock. The shares were purchased at an average cost of $3.46 per share, with a total value of $17,300.00.
• On Monday, July 27th, Amit Kumar acquired 3,188 shares of Anixa Biosciences stock. The shares were purchased at an average cost of $3.37 per share, with a total value of $10,743.56.
• On Monday, July 27th, Amit Kumar bought 5,000 shares of Anixa Biosciences stock. The stock was purchased at an average cost of $3.44 per share, with a total value of $17,200.00.
• On Friday, July 10th, Amit Kumar bought 5,000 shares of Anixa Biosciences stock. The stock was purchased at an average price of $3.04 per share, for a total transaction of $15,200.00.

Anixa Biosciences Price Performance

Shares of ANIX opened at $2.85 on Wednesday. Anixa Biosciences Inc has a 1 year low of $2.32 and a 1 year high of $5.46. The stock’s fifty day moving average price is $3.21 and its two-hundred day moving average price is $2.97. The firm has a market cap of $99.07 million, a PE ratio of -8.91 and a beta of 0.51.

Anixa Biosciences (NASDAQ:ANIX) last posted its quarterly earnings results on Wednesday, September 9th. The company reported ($0.08) earnings per share for the quarter, hitting the consensus estimate of ($0.08). Sell-side analysts anticipate that Anixa Biosciences Inc will post -0.31 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the stock. Weiss Ratings upgraded shares of Anixa Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, September 17th. HC Wainwright dropped their price target on shares of Anixa Biosciences from $7.00 to $6.00 and set a “buy” rating on the stock in a research note on Tuesday, September 22nd. D. Boral Capital reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Anixa Biosciences in a report on Tuesday, June 30th. Wall Street Zen upgraded shares of Anixa Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday, June 20th. Finally, Zacks Research lowered shares of Anixa Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 19th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Anixa Biosciences has an average rating of “Hold” and an average target price of $8.00.

Institutional Investors Weigh In On Anixa Biosciences

Several hedge funds have recently bought and sold shares of ANIX. Renaissance Technologies LLC raised its position in shares of Anixa Biosciences by 13.6% during the 1st quarter. Renaissance Technologies LLC now owns 61,173 shares of the company’s stock valued at $158,000 after buying an additional 7,300 shares in the last quarter. Sanctuary Advisors LLC bought a new stake in shares of Anixa Biosciences during the 2nd quarter worth $29,000. Northwestern Mutual Wealth Management Co. purchased a new position in Anixa Biosciences in the second quarter worth $29,000. Integrated Wealth Concepts LLC purchased a new position in Anixa Biosciences in the second quarter worth $30,000. Finally, Simplicity Wealth LLC bought a new position in Anixa Biosciences in the second quarter valued at $34,000. 29.13% of the stock is currently owned by institutional investors.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc is a clinical-stage biotechnology company focused on developing immunotherapies and vaccines for cancer and infectious diseases. The company’s research programs are designed to use the immune system to prevent or treat serious illnesses.

Anixa’s cancer programs include vaccine approaches for ovarian cancer and triple-negative breast cancer, developed in collaboration with researchers at Cleveland Clinic. The company is also developing chimeric antigen receptor T-cell, or CAR-T, therapies intended to target cancer cells, including programs focused on ovarian cancer.

In addition to oncology, Anixa has pursued vaccine and therapeutic technologies for infectious diseases.